ModernaNamed Top Employer by Science for Fifth Consecutive Year

October 24, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 24, 2019-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced it has been named one of the global biopharmaceutical industry’s top employers in Science and Science Careers’ 2019 Top Employers Survey for the fifth consecutive year. Moderna was ranked 11th on the list this year.

“Moderna’s recent positive Phase 1 readouts from our cytomegalovirus vaccine and chikungunya antibody therapeutic show both the caliber of our science and the relentlessness of our teams to push forward bold ideas,” said Stéphane Bancel, CEO at Moderna. “Many thanks to our employees who have helped make Moderna a Science top employer for five years in a row.”

Since its inception, Moderna has been committed to diversity and creating an environment where all employees can do their best work. Each year, the company has added new industry-leading benefits, including 16 weeks of paid parental leave and 16 weeks of caregiver leave, a sabbatical program that offers four weeks of paid time off after five years of full-time employment with the Company, paid time off for volunteering, and subsidized childcare and public transit.

The annual employee survey evaluates companies in the biopharmaceutical industry in categories such as leadership and direction, work culture and environment, and academic and intellectual challenge. The Science and Science Careers’ 2019 rankings were based on a total sample of 7,658 respondents. The vast majority of survey participants came from North America (72%), Europe (19%) and Asia/Pacific Rim (7%).

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. and Merck, Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com and connect with us on Twitter, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005884/en/

Source: Moderna, Inc.

Media:
Colleen Hussey
Senior Manager, Corporate Communications
203-470-5620
Colleen.Hussey@modernatx.com

Investors:
Lavina Talukdar
Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com